β₂-Adrenergic receptor agonists: a new treatment for diabetic kidney disease?

Am J Physiol Renal Physiol. 2024 Jan 1;326(1):F1-F2. doi: 10.1152/ajprenal.00299.2023. Epub 2023 Nov 2.

Authors

Zhiwen Liu¹, Zheng Dong^{2

3}

Affiliations

¹ Department of Nephrology, The Second Xiangya Hospital at Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, People's Republic of China.
² Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, Georgia, United States.
³ Charlie Norwood Veterans Affairs Medical Center, Augusta, Georgia, United States.

PMID: 37916283
DOI: 10.1152/ajprenal.00299.2023

No abstract available

Keywords: diabetic kidney disease; β2-adrenergic receptor.

Publication types

Editorial
Comment

MeSH terms

Adrenergic Agonists
Animals
Diabetes Mellitus, Experimental*
Diabetic Nephropathies* / drug therapy
Humans
Kidney

Substances

Adrenergic Agonists

Grants and funding